6 Ways to Elevate Your Machine Translation Strategy

Future-proof your MT strategy for clinical and regulatory content with this guide.

AI Driven

With 2025 well underway, innovators in the global life sciences and pharmaceutical industries continue to question how to maximize efficiencies and reduce complexities in clinical and regulatory content development and localization. As part of the broader technological roadmap, AI and automation remain front and center as key players in taking these workflows to new heights. Here are six approaches to ensure you don’t miss a pivotal step when adapting and applying your process.

translation_factory

1. Translation Model Customization

The pharmaceutical industry commands precision and optimal quality in all content. MT models should therefore be tailored and regularly updated such that they align with industry-specific terminology and have built-in glossaries that enforce accuracy and consistency across all translated materials. Using translation memories (TMs) and engine customization with company-specific data enables teams to repurpose pre-approved translations to cut down on review cycle times and ensure content uniformity when compared to “off-the-shelf” machine translation models.

Learn more about how machine translation drives success ›

2. Integration with Clinical & Regulatory Technologies

From a workflow perspective, MT can be integrated directly into additional content repositories, like an eTMF, RIM, web CMS, and more. This generates faster and more secure MT workflows that can be initiated from those same systems where your documents are authored and stored, in a secure “closed loop” ecosystem. In addition, integration with technologies like generative AI and natural language processing can yield more sophisticated language understanding and translation than MT alone. Explore 5 essential use cases for AI automation in regulatory content.

clinical_practice
contact

3. Increased Use of Multimodal Translation

With continually evolving capabilities and new use cases being identified, MT may extend beyond text to include multimodal elements, such as translating audio, images, graphs, and other visual content commonly found in pharmaceutical documents. This could enhance the overall translation of complex information and provide significant efficiencies in areas like patient recruitment and medical information, which more frequently utilize multi-channel and non-document-based content.

4. Enhanced Post-Editing Automation

Automation of post-editing processes has become more sophisticated, mitigating the need for extensive human intervention post-MT. Generative AI tools embedded within the review module leveraged by post-editors results in more streamlined workflows and rapid delivery of high-quality, fully reviewed translations.

post_editing
Forrester TEI GlobalLink for Life Sciences

5. Compliance Monitoring and Reporting

MT systems have evolved to incorporate multifaceted tools, such as built-in compliance monitoring features, ensuring that translations comply with specific regulatory requirements through automated checks for terminology consistency and language compliance, for example.

Key steps for regulatory submissions ›

6. Real-Time Collaboration Tools

The integration of real-time collaboration tools within MT platforms enhances efficiency and enables global teams to work simultaneously on translation projects. Features like live editing, instant feedback, and collaborative workflows help cut down the time needed to make documents submission-ready.

discussion regulatory

Additional Resources & Expert Perspectives

The 5-Step AI Readiness Checklist for Medical Device Manufacturers

Only one in four manufacturers using process AI say it's meeting expectations. The gap between those results and the rest comes down to preparation. This checklist is built from patterns shared by manufacturers that are seeing results, along with the gaps most commonly found among those that aren't. ...

The 5-Step AI Readiness Checklist for Medical Device Manufacturers
Webinar

XTalks | How MI, PV & Regulatory Collaborate on Signals, Labeling, Crisis Response and AI

Medical Information (MI), Pharmacovigilance (PV) and Regulatory Affairs (RA) each play distinct but deeply interconnected roles in ensuring that therapeutics are safe, accurately labeled and compliantly communicated to healthcare professionals and patients. Yet in practice, the ...
Event

C3 Summit 2026 - San Francisco

Conversations on Clinical Content, C3 Summit is part of a series of events hosted by TransPerfect Life Sciences featuring sessions with expert panels discussing present challenges, strategies, and innovations, as well as insights into future advancements, from R&D to ...
Webinar

LifeSci Talks COA Series | Nothing Remains the Same: Why Measures Have to Evolve

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with RJ Wirth, CEO and Consulting Psychometrician at Vector Psychometric Group, to talk about why the measures we rely on are living things rather than fixed artifacts. ...
Blog

Regulatory Considerations for Paper COA Translations | What You Need to Know

Collecting data for a global clinical trial on paper COAs or managing a mixed-mode study that combines both paper and electronic formats means satisfying multiple regulatory bodies before a single patient enrolls. None of these entities operate on the same timeline or...
Blog

When "How Does the Patient Feel?" Became a Regulatory Question

For decades, clinical trials were built around things you could measure with a machine: tumor shrinkage on a scan, laboratory values, and disease progression. These hard, objective endpoints were the backbone of drug approval. The patient's own account of how they felt,...
Webinar

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Despite two decades of technological advancement, the debate between paper and electronic clinical outcome assessments (eCOA) remains unresolved. This webinar revisits the assumptions that continue to shape data collection strategies and examines whether current practice reflects ...

Reach out to our team of AI and MT experts to get started today.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.